Resources about TB
and TB Vaccine R&D
- Meeting Report: Virtual Global Forum on TB Vaccines, 20-22 April 2021, published open access in Vaccine
- TB Vaccines Pipeline Report is a report from Treatment Action Group (TAG) that reviews progress in the clinical development of TB vaccines. The report is updated annually.
- End TB Strategy from the World Health Organization’s Global TB Programme provides a 20-year strategy toward the goal of ending the TB epidemic, including research, development, and implementation of new tools.
- Global Plan to End TB 2023-2030 is a costed plan and roadmap for a concerted response to tuberculosis (TB) aligned with the WHO End TB Strategy, including a strategic framework for TB vaccine R&D.
- WHO Preferred Product Characteristics for New Tuberculosis Vaccine presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy.
- Global Tuberculosis Report, published by the WHO, provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. The report is updated annually.
- TB Vaccine Development Pathway, developed by IAVI and TBVI, is an online tool that provides a structured development path and gating criteria for TB vaccine candidates. It includes considerations for target populations, vaccine platforms, and market, access and implementation, as well as guidance for planning and operating community engagement activities.
- Global Investments in Tuberculosis Research and Development: Past, Present, and Future is a policy paper developed by WHO in collaboration with civil society groups, academia, and product development partnerships to articulate the research and funding needs to end TB.
- TB Research Investments Provide Returns in Combating Both TB and COVID-19 is a policy brief published by Treatment Action Group (TAG) that explores the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and infrastructure established through years of public and donor investments in TB R&D have informed and jump-started COVID-19 research and responses.
- The impact of COVID-19 on the TB epidemic: a community perspective, provides the results of a civil society and affected community led survey to better understand how COVID-19 is impacting key stakeholder groups.
- BCG World Atlas is an interactive map that provides detailed information on current and past BCG vaccination policies and practices for over 180 countries.
Contact us if you have resources about TB and TB vaccines that you would like to share.
Resources for Advocacy and Community Engagement
- The Urgent Need for New TB Vaccines, published by the TB Vaccine Advocacy Roadmap (TBVaxARM), provides information and talking points about the importance of TB vaccines to meeting global targets to end TB and the need to invest in TB vaccine research and development.
- Video - Phumeza Tisile talk about her challenges in facing extensively drug-resistant TB, her vision of a TB free world, and how we can achieve it with new TB vaccines.
- Report on Tuberculosis Research Funding Trends, published annually by TAG, tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects.
- Words Matter, published by Stop TB Partnership, is a communications tool for partners, stakeholders, and anyone affected or working in TB. The guide is a key instrument to encourage positive change, sensitize, promote appropriate language, end the stigmatization, and empower people affected by TB.
- Joint Statement: WHO Director-General and the Civil Society Task Force on TB, a call for increased political commitment and accountability in preparation for the 2023 UN High-Level Meeting on Tuberculosis.
- Good Participatory Practice Guidelines for TB Vaccine Research, published by Aeras, is a user- friendly framework that defines specific standards and key elements needed for creating effective partnerships with stakeholders throughout the entire research process.
- Frequently Asked Questions on TB Vaccine Research, published by IAVI, is a fact sheet that provides information and answers to commonly asked questions about TB vaccine research.
- Myths and Facts about TB Vaccine Research, by IAVI, is a fact sheet that responds to some common misconceptions about vaccine research.
- Tuberculosis Vaccines and Clinical Trials, published by IAVI, provides information about TB, vaccines, and clinical trials in an illustrative and easy to understand booklet.
- Being Part of Tuberculosis Vaccine Clinical Trials is a speaking book published by Books of Hope in collaboration with Aeras, that provides potential clinical trial participants with information about tuberculosis and what is involved in participating in a clinical trial. The information is in both English and Afrikaans.
Contact us if you have advocacy and community engagement resources and materials that you would like to share.
Recent Scientific Publications
- Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT. Cheng P, Xue Y, Wang J, Jia Z, Wang L, Gong W. Front Cell Infect Microbiol. 2022 Nov 2. doi: 10.3389/fcimb.2022.1047306. eCollection 2022.
- Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants. Satti I, Wittenberg RE, Li S, Harris SA, Tanner R, Cizmeci D, Jacobs A, Williams N, Mulenga H, Fletcher HA, Scriba TJ, Tameria M, Haterill M, McShane H. Nat Comm. 2022 Nov 3. Doi: 10.1038/s41467-022-34601-7
- Challenges in TB research. Scriba TJ, Dinkele R, Warner DF, Mizrahi V. J Exp Med. 2022 Nov 3. Doi: 10.1084/jem.20221334. Online ahead of print.
- Immunologic Role of Innate Lymphoid Cells against Mycobacterial tuberculosis Infection. Narinyan W, Poladian N, Orujyan D, Gargaloyan A, Venketaraman V. Biomedicines. 2022 Nov 6. doi: 10.3390/biomedicines10112828.
- Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis. Jayawardana S, Weerasuriya CK, Pelzer PT, Seeley J, Harris RC, Tameris M, Tait D, White RG, Asaria M. NPJ Vaccines. 2022 Nov 7. doi: 10.1038/s41541-022-00554-1
- Histopathologic differences in granulomas of Mycobacterium bovis bacille Calmette Guérin (BCG) vaccinated and non-vaccinated cattle with bovine tuberculosis. Kanipe C, Boggiatto, PM, Putz EJ and Palmer, MV. Front Microbiol. 2022 Nov 8. doi: 10.3389/fmicb.2022.1048648
- Mycobacterium tuberculosis: Implications of Ageing on Infection and Maintaining Protection in the Elderly. Bonavida V, Frame M, Nguyen KH, Rajurkar S, Venketaraman V. Vaccines(Basel). 2022 Nov 9. doi:10.3390/vaccines10111892
- Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses. Coccia M, Burny, W, Demoitie MA, Gillard P, van den Berg RA, van der Most R. 2022 Nov 10. PLoS One. doi: 10.1371/journal.pone.0276505
- Enhanced immunogenicity of Mycobacterium bovis BCG through CRISPRi mediated depletion of AftC. Madduri BTSA, Allen L, Taylor SC, Besra GS, Alderwick LJ. Cell Surf. 2022 Nov 11. doi: 10.1016/j.tcsw.2022.100088. eCollection 2022 Dec.
- National TB elimination programme – What has changed. Khanna A, Saha R, Ahmad N. 2022 Nov 16. Indian J Med Microbiol. doi: 10.1016/j.ijmmb.2022.10.008
- BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes. Takahashi H, Kuhtreiber WM, Keefe RC, Lee AH, Aristarkhova A, Dias HF, Ng N, Nelson KJ, Bien S, Scheffrey D, Faustman DL. Sci Adv. 2022 Nov 18. doi: 10.1126/sciadv.abq7240
- Activation of Nrf2 modulates protective immunity against Mycobacterium tuberculosis infection in THP1-derived macrophages. Zhou J, Fang F, Qi J, Li T, Zhang L, Liu H, Lv J, Xu T, Wu F, Song C, Li W, Wang X, Chang X, Wang H, Wang T, Qian Z. Free Radic Biol Med. 2022 Nov 20. doi: 10.1016/j.freeradbiomed.2022.10.274. Epub 2022 Oct 14.
- Can BCG vaccination at first health-facility contact reduce early infant mortality? Study protocol for a cluster-randomised trial (CS-BCG). Thysen SM, Jensen AM, Vedel JO, da Silva Borges I, Aaby P, Jensen AKG, Benn CS, Fisker AB. BMJ. 2022 Nov 21. doi: 10.1136/bmjopen-2022-063872
- Pathogenicity and virulence of Mycobacterium tuberculosis. Rahlwes Kathryn C, Dias Beatriz RS, Campos Priscila C, Alvarez-Arguedas S, Shiloh Michael U. Virulence. 2022 Nov 23. doi: 10.1080/21505594.2022.2150449. Online ahead of print.
- Manganese enhances macrophage defense against Mycobacterium tuberculosis via the STING-TNF signaling pathway. Qian K, Shan L, Shang S, Li T, Wang S, Wei M, Tang B, Xi J. Int Immunopharmacol. 2022 Nov 23. doi: 10.1016/j.intimp.2022.109471. Online ahead of print
- First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world. Lu J, Zhang X, Xu H, Li Z. Hum Vaccin Immunother. 2022 Nov 30. doi: 10.1080/21645515.2022.2080443
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D